Develops therapies for rare pediatric diseases and other conditions, focusing on improving pediatric healthcare outcomes.
Quoin Pharmaceuticals, Ltd. is an innovative clinical-stage specialty pharmaceutical company specializing in the development and commercialization of therapeutic solutions for rare and orphan diseases. Founded in 2018 and headquartered in Ashburn, Virginia, Quoin Pharmaceuticals is dedicated to addressing unmet medical needs through its robust pipeline of novel treatments.
The company's flagship product, QRX003, is a topical lotion specifically formulated for the treatment of Netherton Syndrome (NS), a rare genetic skin disorder. Quoin Pharmaceuticals is also advancing QRX004, aimed at addressing recessive dystrophic epidermolysis bullosa, QRX007 for additional treatments of NS, and QRX008 targeting scleroderma. These initiatives underscore the company's commitment to advancing therapies that can potentially transform the lives of patients suffering from severe dermatological and autoimmune conditions.
In addition to its internal development programs, Quoin Pharmaceuticals has established strategic partnerships and agreements to bolster its research and commercialization efforts. These include licensing agreements with Skinvisible Inc., consulting collaborations with Axella Research LLC, a Master Service Agreement with Therapeutics Inc., and a research partnership with Queensland University of Technology. With a strong focus on scientific innovation and therapeutic advancement, Quoin Pharmaceuticals continues to make significant strides towards improving patient outcomes and reshaping the landscape of rare disease treatment.